Pioglitazone is a product developed by Japan's Takeda/Eli Lilly. It was approved by the FDA on July 15, 1999 and was launched in the United States under the trade name "Actos". Of the global market sales of US$2.297 billion in 2005, Takeda accounted for 79%, and Eli Lilly and Company’s share was only 21%. In 2005, Japan’s Takeda’s original drug was registered in my country under the trade name “Acto” "Listed.
Pioglitazone was developed earlier in my country. In 2001, after the successful joint development between the China Medical Research and Development Center, Beijing Taiyang Pharmaceutical, Shanghai Institute of Medical Technology, and Jiangsu Hengrui Medicine, it obtained a new drug certificate and production as an innovative drug. Approval. Subsequently, Shandong Pharmaceutical Industry Research Institute, Shandong Chengchuang Pharmaceutical, and Beijing Xinghao Modern Medicine successively obtained new drug certificates. As of now, SFDA has approved 10 domestic raw material and preparation manufacturers, 11 preparation manufacturers, and 1 raw material manufacturer.
The difference between pioglitazone and other varieties in the domestic market is that its domestically produced drugs have dominated the domestic market, accounting for more than 80% of the market share. There are 12 pioglitazone manufacturers for domestic sample hospitals, among which the top five are "Aitin" of Beijing Taiyang Pharmaceutical, "Ruitong" of Jiangsu Hengrui Pharmaceutical, and "Cast" of Hangzhou Zhongmei Huadong Pharmaceutical. "Ping", "Acto" of Tianjin Takeda Pharmaceuticals, and "Beitangning" of Sichuan Baoguang Pharmaceuticals accounted for 98.27 shares, while 7 companies including Zhejiang Conba Pharmaceuticals, Shanghai Kaibao Pharmaceuticals, and Shandong Zibo Xinda Pharmaceuticals products accounted for only 1.73. Although it is still in its infancy, it is also showing rapid growth.
Generally speaking, chemical drugs are still the main force in the treatment of diabetes, and the application of new drug release technologies and the development of compound preparations have become the direction of current drug use. Japan’s Takeda Pharmaceutical’s pioglitazone/glimepiride After its compound preparation (Duetact) was launched in the United States, it was approved for marketing by the European Commission. This further revealed that combined medication is more conducive to early protection of pancreatic beta cell function in diabetic patients, thereby conducive to long-term blood sugar control.
On the other hand, with the gradual formation of the world's return to natural craze, plant-extracted drugs also have good development prospects. Many single drugs or compound preparations show multiple hypoglycemic mechanisms, such as stimulating pancreatic beta cells to secrete insulin, inhibiting glucagon secretion, increasing insulin receptor sensitivity, inhibiting intestinal absorption of glucose, and improving fatty acids. Metabolism, etc., and the combined application of chemical drugs and plant extract drugs will have positive significance in the prevention and treatment of diabetes and its complications.
The two main types of thiazolidinediones commonly used in clinical practice are rosiglitazone and pioglitazone. Clinically, it is used as an insulin sensitizer to increase the body's sensitivity to insulin and reduce insulin resistance.